12:00 AM
 | 
Dec 03, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Exjade deferasirox regulatory update

EMA's CHMP issued a positive opinion recommending expanding the label of Exjade deferasirox to include treatment of chronic iron overload requiring chelation therapy when deferoxamine therapy is contraindicated or...

Read the full 123 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >